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BACKGROUND: The advent of highly active antiretroviral therapy (HAART) in 1996 led to a decrease in the incidence of Kaposi’s
sarcoma (KS) and non-Hodgkin’s lymphoma (NHL), but not of other cancers, among people with HIV or AIDS (PWHA). It also led
to marked increases in their life expectancy.
METHODS: We conducted a record-linkage study between the Swiss HIV Cohort Study and nine Swiss cantonal cancer registries.
In total, 9429 PWHA provided 20 615, 17 690, and 15 410 person-years in the pre-, early-, and late-HAART periods, respectively.
Standardised incidence ratios in PWHA vs the general population, as well as age-standardised, and age-specific incidence rates were
computed for different periods.
RESULTS: Incidence of KS and NHL decreased by several fold between the pre- and early-HAART periods, and additionally declined
from the early- to the late-HAART period. Incidence of cancers of the anus, liver, non-melanomatous skin, and Hodgkin’s lymphoma
increased in the early- compared with the pre-HAART period, but not during the late-HAART period. The incidence of all
non-AIDS-defining cancers (NADCs) combined was similar in all periods, and approximately double that in the general population.
CONCLUSIONS: Increases in the incidence of selected NADCs after the introduction of HAART were largely accounted for by the
ageing of PWHA.
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The introduction of highly active antiretroviral therapy (HAART)
in 1996 has greatly influenced the pattern of cancer incidence in
people with HIV or AIDS (PWHA). The decrease in the prevalence
of severe immunodeficiency has resulted in a rapid reduction in
Kaposi’s sarcoma (KS) (Ledergerber et al, 1999; Franceschi et al,
2008; Polesel et al, 2008) and non-Hodgkin’s lymphoma (NHL)
incidence (Polesel et al, 2008; The COHERE Study Group, 2009).
However, improved PWHA survival has been accompanied by an
increase in the burden of non-AIDS-defining cancers (NADCs)
(Engels et al, 2008).
The Swiss HIV Cohort Study (SHCS) is a large prospective
cohort that has been ongoing for 20 years and is characterised by
detailed follow-up information, excellent treatment standards, and
the possibility to link with population-based cancer registries. As
such, it offers an especially good opportunity to monitor changes
in the pattern of cancer incidence in PWHA (Clifford et al, 2005;
Franceschi et al, 2008; Polesel et al, 2008). It is now possible to add
four additional years of follow-up to our linkage study of the SHCS
and Swiss cancer registries, and thus to evaluate the long-term
consequences of HAART use, particularly with respect to NADCs.
The aim of our present report is to evaluate the changes in
patterns of cancer incidence in the SHCS in three different periods
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(pre-HAART, 1985– 1996; early HAART, 1997– 2001; and late
HAART: 2002–2006), while taking into account large shifts in the
age distribution of PWHA.
MATERIALS AND METHODS
The SHCS has been enrolling PWHA who are 416 years of age
from seven large hospitals in different Swiss cities (Basel, Bern,
Geneva, Lausanne, Lugano, St Gallen, and Zurich) since 1988, with
some retrospective enrolment going back to 1985 (The Swiss HIV
Cohort Study, 2010). Once written informed consent is obtained,
detailed information (including demographic and clinical charac-
teristics) is collected. Follow-up visits are scheduled at 6-month
intervals and include updating information on selected disease
diagnoses, laboratory test results, and HIV/AIDS-related treat-
ments. Only AIDS-defining cancers (KS, NHL, and, since 1993,
invasive cervical carcinoma) (Ancelle-Park, 1993) and Hodgkin’s
lymphoma have been systematically reported in the SHCS since
the beginning of the study.
Nine active cancer registries, covering 56% of the Swiss
population, collect population-based quality-checked data on
cancer incidence in Switzerland (Curado et al, 2007). The Cancer
Registries of the Cantons of Basel, Geneva, St Gallen and
Appenzell, Ticino, Vaud, and Zurich overlap directly with six
of the seven regions covered by SHCS centres (all except the
Bern SHCS Centre) (Clifford et al, 2005).
Swiss cancer registries vary greatly both in size of population
coverage (from 165 000 in Neuchatel to 1168 000 in Zurich) and
year of initiation of cancer registration (from 1970 in Geneva to
1996 in Ticino). Routine indicators of data completeness and
quality in the Swiss registries are very good (Parkin et al, 2002;
Curado et al, 2007).
Record linkage was performed using an upgraded version of an
ad hoc software application that was previously designed and
validated in Italy and Switzerland (Geneva) to match individuals
from AIDS and cancer registries while protecting patient
anonymity (Dal Maso et al, 2001; Clifford et al, 2005). Each
SHCS centre holds its own nominal participant records. Thus, each
SHCS database was independently matched with the corres-
ponding cantonal cancer registry. Furthermore, to account for
inter-cantonal migration and health-care mobility, cross-cantonal
linkage within neighbouring cancer registries, including those
that do not overlap with SHCS centres (i.e., Neuchatel, Valais, and
Glarus Graubunden), was also conducted. Personal identifiers were
never made visible during linkage procedures, nor were they
included in the output file.
From January 1985 through May 2007, 14 560 PWHA (median
age, 33 years; 95% range, 22–54) were enrolled in the SHCS.
PWHA were excluded (in hierarchical order) from this report
if they: (1) did not report a legal residence in a canton covered by
a cancer registry with which their SHCS records were linked
(n¼ 4512, principally those from the Bern SHCS Centre); (2) were
followed by a private physician and were unavailable for
name-based linkage (n¼ 60); (3) their follow-up in the SHCS
did not correspond to years for which data were available in cancer
registries (n¼ 520); or (4) were o16 years (n¼ 4) or 469 years
of age (n¼ 35) at enrolment. Eventually, 9429 PWHA (median age,
32 years; 95% range, 22–53) were included. Of these, 29%
were women and 18.1% had AIDS at study entry. For each
PWHA included in the study, the relevant time period for the
calculation of person-years at risk began 3 months after the date
of SHCS enrolment and ended at 70 years of age, the date of last
SHCS information, cancer diagnosis, or death, whichever was
earliest.
Observed cancers included incident cases reported to cancer
registries during the above-defined person-years at risk. In all,
103 cases of KS, 23 NHL, 3 invasive cervical carcinomas, and
10 NADCs diagnosed between 0 and 3 months after SHCS
enrolment were considered prevalent cases and were not included.
Cancers were classified according to the International Classifica-
tion of Diseases for Oncology, Third Edition (Fritz et al, 2000),
and according to the International Classification of Diseases
and Related Health Problems, 10th Revision (World Health
Organisation, 1992).
This study was approved by the ethics committees of the SHCS
and the International Agency for Research on Cancer. All patients
in the SHCS gave written informed consent.
Statistical methods
Expected numbers of cancers were computed from cancer registry-,
sex-, age-, and period-specific incidence rates (IRs) (Parkin
et al, 1992, 1997, 2002; Curado et al, 2007) for three periods
(pre-HAART, 1985–1996; early HAART, 1997–2001; late HAART,
2002–2006). Observed numbers of cancers in PWHA were
compared with expected numbers by standardised incidence ratios
(SIRs). Corresponding 95% confidence intervals (CIs) were
computed using the Poisson distribution (Breslow and Day,
1987). All cancers other than KS, NHL, and invasive cervical
carcinoma were grouped as NADCs. AIDS-defining cancers and
NADCs were further combined into an ‘all cancers’ category.
The IRs among PWHA were also computed separately for the
pre-, early-, and late-HAART periods. As the purpose was to make
comparisons within the SHCS, IRs were standardised for age
(5-year groups) and sex (when appropriate), using the direct
method (Breslow and Day, 1987) and the age and sex structure of
all PWHA included in this study as a standard population. The
95% CIs of IRs and of IR ratios in different periods were computed
according to the Poisson distribution.
Age-specific IRs (i.e., 25–34, 35–44 and 45–54, and 55– 69
years) and corresponding 95% CIs were computed for selected
NADCs separately in two periods (the pre-HAART and the HAART
periods). Age-specific IRs were internally standardised for age
(5-year groups) and sex (when appropriate) based on the distri-
bution of all PWHA included in this study. For comparison
purposes, the corresponding age-specific IRs published for
1998– 2002 in the general population from the same Swiss cantons
were also computed (Curado et al, 2007).
RESULTS
Among 9429 SHCS participants followed for a total of 53 715
person-years, 858 cancers were identified (Table 1). Observed and
expected numbers and corresponding SIRs in the pre-, early-, and
late-HAART periods are shown for cancer sites or types with at
least two cases observed. The SIRs of KS, NHL, and invasive
cervical carcinoma declined by several fold. The SIRs for some
individual NADCs (i.e., anus, liver, and non-melanomatous skin)
increased between the pre- and early-HAART periods, but not
between the early- and late-HAART periods. The SIR for
Hodgkin’s lymphoma increased greatly between the pre- (9.2)
and the early-HAART (21.0) periods, but little thereafter (28.1).
The SIRs for cancer of the head and neck and the lung did not
change, whereas the SIR for multiple myeloma declined. The SIRs
for all NADCs combined did not substantially change by period.
The SIR for the combination of all cancers diminished from 17.6
(95% CI, 16.1–19.1) in the pre-HAART to 3.0 (95% CI, 2.6–3.6) in
the late-HAART period (Table 1).
Table 2 is restricted to cancers with 410 cases observed after
the introduction of HAART. Age-standardised IRs in the pre-,
early-, and late-HAART periods with corresponding IR ratios are
shown. Large decreases of IRs for KS, NHL, and all cancers were
observed between the pre- and early-HAART periods, whereas no
significant change was found for NADCs (IR ratio, 1.2; 95% CI, 0.9–1.7).
Cancer incidence and ageing in the SHCS
S Franceschi et al
417
British Journal of Cancer (2010) 103(3), 416 – 422& 2010 Cancer Research UK
E
p
id
e
m
io
lo
g
y
Table 1 Observed and expected numbers of cancers, SIRs, and 95% CIs among PWHA by period of cancer diagnosis
Period
Pre-HAART
(1985–1996) 20 615 PY
Early-HAART
(1997–2001) 17 690 PY
Late–HAART
(2002–2006) 15 410 PY
Cancer site or type (ICD10) O/E SIR 95% CI O/E SIR 95% CI O/E SIR 95% CI
AIDS-defining cancers
Kaposi’s sarcoma (C46) 272/1.1 246 218–277 35/0.7 47.8 33.3–66.6 14/0.6 22.9 12.5–38.5
Non-Hodgkin’s lymphoma (C82-C88, C96) 191/1.9 103 88.8–119 52/1.9 26.7 19.9–35.1 32/2.0 16.2 11.1–22.9
Cervix uteri (C53) 4/0.5 8.4 2.2–21.8 2/0.5 3.7 0.3–13.6 0/0.5 — —
All AIDS-defining cancers 467/3.4 136 124–149 89/3.2 27.7 22.2–34.1 46/3.1 14.7 10.8–19.6
Non-AIDS-defining cancers
Head and neck (C00-C14, C30-C32)a 9/2.1 4.3 2.0–8.3 8/2.7 2.9 1.3–5.8 7/3.2 2.2 0.9–4.5
Stomach (C16) 1/0.7 1.5 0.0–8.5 1/0.9 1.2 0.0–6.7 1/1.0 1.0 0.0–5.6
Small intestine, colon, rectum and rectosigmoid
junction (C17-C20)
2/1.8 1.1 0.1–4.0 2/2.8 0.7 0.1–2.6 1/3.5 0.3 0.0–1.6
Anus (C21) 2/0.1 25.7 2.4–94.5 12/0.1 112 57.8–197 6/0.1 49.9 18.0–109
Liver (C22) 2/0.4 5.5 0.5–20.2 7/0.7 10.7 4.2–22.2 5/0.8 6.1 1.9–14.3
Pancreas (C25) 0/0.4 — — 2/0.6 3.4 0.3–12.4 1/0.7 1.4 0.0–7.8
Trachea, lung and bronchus (C33, C34) 8/2.4 3.3 1.4–6.6 10/3.6 2.8 1.3–5.1 12/4.6 2.6 1.3–4.6
Skin, melanomatous (C43) 3/2.5 1.2 0.2–3.5 2/3.1 0.6 0.1–2.4 6/3.1 2.0 0.7–4.3
Skin, non-melanomatous (C44) 7/4.0 1.7 0.7–3.6 23/6.5 3.5 2.2–5.3 23/7.0 3.3 2.1–4.9
Breast (C50)b 1/1.7 0.6 0.0–3.4 4/3.3 1.2 0.3–3.2 4/4.3 0.9 0.2–2.4
Ovary (C56) 2/0.3 6.4 0.6–23.5 0/0.4 — — 0/0.5 — —
Prostate (C61) 0/1.1 — — 5/2.8 1.8 0.6–4.1 5/3.8 1.3 0.4–3.1
Testis (C62) 4/3.0 1.3 0.3–3.4 3/2.4 1.2 0.2–3.7 1/1.8 0.5 0.0–3.1
Kidney (C64) 1/0.5 1.9 0.0–10.6 1/0.8 1.3 0.0–7.2 3/1.0 3.1 0.6–9.2
Bladder (C67) 1/1.0 1.1 0.0–6.0 0/1.4 — — 1/1.7 0.6 0.0–3.3
Brain, meninges and central nervous systems (C70-C72) 2/0.9 2.2 0.2–7.9 2/0.9 2.2 0.2–8.0 0/1.0 — —
Thyroid (C73) 2/0.7 2.9 0.3–10.7 1/0.8 1.2 0.0–7.0 0/0.8 — —
Hodgkin’s lymphoma (C81) 7/0.8 9.2 3.6–19.0 12/0.6 21.0 10.8–36.8 13/0.5 28.1 14.9–48.2
Multiple myeloma (C90) 3/0.2 14.8 2.8–43.9 1/0.3 3.2 0.0–18.1 2/0.4 5.1 0.5–18.9
Leukaemias (C91-C95) 1/0.7 1.5 0.0–8.3 2/0.8 2.4 0.2–8.8 1/0.9 1.1 0.0–6.5
All non-AIDS-defining cancersc 62/26.7 2.3 1.8–3.0 100/37.3 2.7 2.2–3.3 94/42.8 2.2 1.8–2.7
All cancers 529/30.1 17.6 16.1–19.1 189/40.6 4.7 4.0–5.4 140/46.0 3.0 2.6–3.6
Abbreviations: CI¼ confidence intervals; E¼ expected; HAART¼ highly active antiretroviral therapy; O¼ observed; PWHA¼ people with HIV or AIDS; PY¼ person years;
SIRs¼ standardised incidence ratios. aIncludes nine tongue, six mouth, three larynx cancers, and one cancer each of lip, tonsil, oropharynx, nasopharynx, hypopharynx, and nasal
cavity. bFemales only. cAlso includes four unknown primary sites plus one cancer each of the oesophagus, biliary tract, connective/soft tissue, and corpus uteri.
Table 2 IRsa ( 100 000), and IR ratios and corresponding 95% CIs for selected cancersb among PWHA by period of cancer diagnosis
Period
Pre-HAART
(1985–1996)
20 615 PY
Early-HAART
(1997–2001)
17 690 PY
Late-HAART
(2002–2006)
15 410 PY
IR ratio (95% CI) IR ratio (95% CI)
Cancer site or type (ICD10) O IR 95% CI O IR 95% CI O IR 95% CI early vs pre late vs early
AIDS-defining cancers
Kaposi’s sarcoma (C46) 272 1375 1213–1551 35 194 123–285 14 66.9 29.5–123 0.1 (0.1–0.2) 0.3 (0.2–0.7)
Non-Hodgkin’s lymphoma
(C82-C88, C96)
191 952 818–1102 52 252 176–347 32 98.4 66.1–141 0.3 (0.2–0.4) 0.4 (0.2–0.6)
All AIDS-defining cancersc 467 2283 2075–2505 89 442 336–566 46 163 112–226 0.2 (0.1–0.3) 0.4 (0.2–0.6)
Non-AIDS-defining cancers
Head and neck (C00-C14, C30-C32) 9 41.6 18.8–79.3 8 37.2 15.0–75.3 7 19.2 7.7–39.8 0.9 (0.3–2.4) 0.5 (0.2–1.4)
Anus (C21) 2 8.3 0.9–30.1 12 42.7 21.9–74.7 6 25.3 7.3–58.8 5.2 (1.3–21.3) 0.6 (0.2–1.7)
Liver (C22) 2 9.6 1.1–34.7 7 25.9 10.4–53.5 5 17.1 5.1–40.9 2.7 (0.5–13.9) 0.7 (0.2–2.1)
Trachea, lung, and bronchus (C33, C34) 8 38.1 16.3–75.3 10 36.5 17.4–67.2 12 33.9 17.2–59.7 1.0 (0.4–2.4) 0.9 (0.4–2.2)
Skin, non-melanomatous (C44) 7 35.8 14.1–74.3 23 85.7 53.7–129 23 86.8 48.1–140 2.4 (1.0–5.7) 1.0 (0.5–1.9)
Hodgkin’s lymphoma (C81) 7 30.7 12.2–63.5 12 42.9 20.8–77.0 13 52.8 20.2–102 1.4 (0.5–3.7) 1.2 (0.5–3.1)
All non-AIDS-defining cancers 62 320 242–414 100 397 316–491 94 324 250–410 1.2 (0.9–1.7) 0.8 (0.6–1.1)
All cancers 529 2602 2379–2840 189 839 704–990 140 487 395–590 0.3 (0.3–0.4) 0.6 (0.4–0.8)
Abbreviations: CI¼ confidence interval; HAART¼ highly active antiretroviral therapy; IR¼ incidence rate; O¼ observed; PWHA¼ people with HIV or AIDS; PY¼ person years.
aRates are standardised by 5-year age group and sex, based on the age and sex distribution of all PWHA included in this study; bCancers diagnosed in 410 PWHA in the
HAART period; cIncluding cervix uteri (C53).
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Increases were observed, however, from the pre- to early-HAART
period, for cancer of the anus (IR ratio, 5.2; 95% CI, 1.3–21.3) and
non-melanomatous skin cancer (IR ratio, 2.4; 95% CI, 1.0–5.7).
When IRs of selected cancers in the early- and late-HAART periods
were compared, additional declines in KS (IR ratio, 0.3; 95% CI,
0.2–0.7), NHL (IR ratio, 0.4; 95% CI, 0.2–0.6) and all cancers
(IR ratio, 0.6; 95% CI, 0.4–0.8) were found. The IR ratios (late- vs
early-HAART period) for individual NADCs or their combinations
were close to unity (lung, non-melanomatous skin, Hodgkin’s
lymphoma) or non-significantly below unity (head and neck, anus
and liver) (Table 2).
Figure 1 shows the steep downward trends in the IRs for all
cancers, by gender. Decreases were greater among men than
women and among men having sex with men than heterosexuals
and intravenous drug users. The IRs for all cancers in the two sexes
and in the three HIV-transmission categories became similar in the
late-HAART period (Figure 1).
Age-specific IRs for cancer of the anus, liver, lung, non-
melanomatous skin, Hodgkin’s lymphoma, and all NADCs
combined in PWHA in the pre-HAART and the HAART periods,
and, for comparison purposes, in the general population
(1998–2002), are shown in Figure 2. Cancer cases were extremely
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few in the pre-HAART period, especially in PWHA aged X35
years. The 95% CIs of age-specific IRs for individual NADCs in
PWHA in the pre-HAART and HAART periods always overlapped.
In the HAART periods, 95% CIs of IRs for cancer of the anus,
liver, lung, non-melanomatous skin, Hodgkin’s lymphoma, and all
NADCs combined did not overlap with IRs from the general
population in the 35– 44- and 45–54-year age groups. In the 55-69-
year age group, only for anal cancer did the IR in the HAART
periods not overlap with the corresponding IR in the general
population (Figure 2).
DISCUSSION
In this paper, we used SIRs to compare cancer excess in PWHA
with that in previous studies (Clifford et al, 2005; van Leeuwen
et al, 2009; Dal Maso et al, 2009), and IRs to evaluate cancer trends
within the SHCS. Trends in cancer incidence in SHCS participants
in the last two decades has been dominated by the favourable
trends in KS and NHL. All cancer incidence (including both
AIDS-defining cancers and NADCs) decreased in the late-HAART
period by 81% compared with the pre-HAART period. Further-
more, mainly because of the decline in KS, previously large
differences in cancer incidence between men and women, as well
as between men having sex with men, heterosexuals, and
intravenous drug users, have disappeared.
Further decreases in the incidence of KS and NHL also emerged
between the early- and late-HAART periods. In the late-HAART
period, treatment options increased and the risk of untreated
viraemia became better appreciated than before (Hammer et al,
2008). Virological and immunological outcomes of initial HAART
improved between 2000–2001 and 2004–2005 in the SHCS
(Vo et al, 2008). Indeed, a higher proportion of KS and NHL
occurred in HAART-naı¨ve PWHA in the early-HAART (46%) than
in the late-HAART (27%) period (data not shown).
This study also showed that the incidence of all NADCs
combined did not increase between the pre-HAART and HAART
periods, even though by the late-HAART period it had become
higher than the declining incidence of KS and NHL combined. In
other studies using differently defined populations (e.g., HIV-
positive people or people with AIDS only) and different statistical
approaches (SIR or age-standardised IRs), increases in NADCs
have been reported since the introduction of HAART (Engels et al,
2008; Patel et al, 2008; Dal Maso et al, 2009; Guiguet et al, 2009; van
Leeuwen et al, 2009), especially for cancer of the anus (Piketty
et al, 2008; Chaturvedi et al, 2009), liver (Rosenthal et al, 2007;
Polesel et al, 2010), lung (Bower et al, 2003; Kirk et al, 2007), and
Hodgkin’s lymphoma (Biggar et al, 2006). Thus, concerns have
been raised that HAART or its consequences (immune reconstitu-
tion) may have directly contributed to the increase of certain
NADCs (Hammer et al, 2008).
Drugs included in HAART have been attributed to both
carcinogenic (e.g., incorporation of zidovudine into nuclear DNA
and alteration of the expression of several cell-cycle genes)
(Olivero, 2007) and anti-tumour (anti-angiogenic effect of protease
inhibitors) (Monini et al, 2004) effects. Zidovudine and zalcitabine
have been classified in an International Agency for Research on
Cancer Monograph (IARC, 2000) as ‘possibly carcinogenic to
humans’ on the basis of inadequate evidence in humans, but
sufficient evidence of carcinogenicity in experimental animals
(IARC, 2000). The hepatotoxicity of HAART was suspected to
worsen the effect of hepatitis B and C infection on the risk of liver
cancer (Puoti et al, 2004). Hodgkin’s lymphoma was reported to
occur more frequently in AIDS patients with moderate than severe
immunosuppression in the United States (Biggar et al, 2006), as
well as among those using non-nucleoside reverse transcription
inhibitors in the United Kingdom (Powles et al, 2009). The
possibility of some adverse effect of HAART on cancer risk will
be raised again, and it is therefore important to use adequate
monitoring tools to account for the concurrent dramatic increase
in the life expectancy of PHWA (Polesel et al, 2010).
The SIRs for a few NADCs (anus, liver, non-melanomatous skin,
and Hodgkin’s lymphoma) increased in the SHCS after the
introduction of HAART. At the same time, however, SHCS
participants had grown older (the proportion of person-years
from PWHA aged X35 years had increased from 38% in the
pre-, to 67% in the early-, and 81% in the late-HAART period).
The SIRs, however, are based on the indirect adjustment
method, meaning that a standard population (the general Swiss
population) provides the rates, and the study population (PWHA)
provides the weights (age and sex structure) (Schoenbach, 2000).
Hence, if the PWHA age structure changes substantially, the
comparison of SIRs over time becomes problematic. Using,
more correctly, IRs age-standardised by the direct method (the
application of age-specific IRs among PWHA in different periods
to the age and sex structure of the same standard population, i.e.,
PWHA over the entire study), cancers of the anus and non-
melanomatous skin were the only malignancies to increase
significantly, and only between the pre- and the early-HAART
periods in the SHCS. Although the direct method gives greater
comparability, it requires more data than the indirect method
(Schoenbach, 2000). Therefore, even for the most frequent NADCs,
the low number of cancer cases made the standardisation process
unstable. Indeed, the 95% CI of age-specific IRs in PWHA in the
pre-HAART and HAART periods broadly overlapped for indivi-
dual NADCs, as well as for all NADCs combined.
Five individual NADCs showed a clear excess in the HAART
periods among PWHA compared with the general population,
regardless of statistical approach. Three of these NADCs (anus,
liver, and Hodgkin’s lymphoma) have a well-established viral
aetiology (human papillomavirus (IARC, 2007), hepatitis B and C
viruses (IARC, 1994), and Epstein–Barr virus (IARC, 1997),
respectively). Contrary to KS and some types of NHL, a long
latent period separates the infection with the responsible virus and
the onset of cancer of the anus and liver. A viral aetiology for non-
melanomatous skin cancer is not yet well established, except for
the rare polyomavirus-associated Merkel cell carcinoma (Lanoy
et al, 2009). Previous studies suggested that smoking could not
totally account for the increases in lung cancer (The D:A:D Study
Group, 2006; Chaturvedi et al, 2007), and that impaired immunity
was associated with liver disease and liver cancer among PWHA
infected with hepatitis B and C viruses (Clifford et al, 2008). The
effect of HIV-related immunodeficiency on cancers of the lung and
liver remains, however, ill-defined (Bouvard et al, 2009).
The SHCS has many strengths, including the length and
completeness of follow-up and the good representation of women
and different HIV-transmission categories (The Swiss HIV Cohort
Study, 2010). Furthermore, the SHCS has been estimated to cover
45% of the cumulative number of HIV infections declared to the
Swiss health authorities and 69% of registered AIDS cases, making
the study unique in terms of population representativeness. The
possibility of record linkage with high-quality cancer registries
improved the completeness and quality of cancer-related informa-
tion (e.g., histological confirmation) beyond what was available in
the SHCS records.
The most important limitations of this study are 1) the relatively
small number of individual NADCs, and 2) the complexity of
adjusting for large decreases in competing non-cancer risks among
PWHA (Keiser et al, 2004) without making implausible assump-
tions about the way removal of competing risks would have
affected cancer risk (Rothman et al, 2008). Problems typical of
record-linkage studies, for example, inaccuracies in personal
identifiers and self-reported legal residence that may result in
some undermatching between the SHCS participants and cancer
registry records, cannot be completely excluded, but should have
been largely avoided. With respect to surveillance bias, no
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difference was found in the risk of cancers in which screening can
make a substantial difference (e.g., cancer of the colon–rectum,
breast, prostate, and thyroid). Part of the excess of cancer of the
anus and non-melanomatous skin, however, may be due to a more
intense search and more accurate diagnosis of these cancers in
PWHA than in the general population.
In conclusion, our study showed that the incidence of KS and
NHL continued to decline from the early- to the late-HAART
period, but the incidence of NADCs did not change substantially.
Estimates of the excess of cancers of the anus, liver, lung, non-
melanomatous skin and Hodgkin’s lymphoma in PWHA compared
with the general population (expressed as SIRs or age-specific IRs)
became more precise in the HAART periods. Comparisons of the
incidence of NADCs among PWHA in the pre-HAART and HAART
periods remained very difficult, but they did not support claims of
an adverse influence of HAART per se or HAART-related immune
reconstitution on cancer risk.
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Laboratory Committee), CA Fux, M Gorgievski, HF Gu¨nthard
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